Top 50 Ai For Computational Biology in Europe

Bioptimus is developing a universal AI foundation model specifically for biological research, enabling researchers to leverage large-scale data analysis and predictive modeling. This technology addresses the challenge of slow and fragmented discovery processes in biomedicine by providing a cohesive platform for accelerating insights and innovations.

The startup develops a drug discovery platform that combines artificial intelligence and synthetic biology to digitize natural diversity and identify potential drug candidates based on their functions. This approach aims to make the discovery of new therapeutics for cancer, metabolic diseases, and infectious diseases more predictable and cost-effective.

The startup has developed an artificial intelligence platform for biomarker discovery and sequencing analysis, focusing on extracting biosignatures from single-cell and multi-omics data. This platform enables physicians to efficiently analyze complex disease patterns, reducing data processing time and costs while enhancing insights for patient stratification.

The startup offers a bioinformatics platform that enables researchers to analyze and explore omics data through features like pathway analysis, data visualization, and database searches. This platform simplifies the complex process of omics data interpretation, enhancing the efficiency of academic research.

The startup develops gene therapies using artificial intelligence to enhance the design and optimization of genetic constructs. Their technology enables researchers to create more predictable and controllable gene therapies, facilitating faster development for various applications.

The startup has developed a digital diagnostics platform that utilizes artificial intelligence for genetic analysis and clinical decision support, enhancing the traceability and interoperability of bioinformatics data. This technology enables researchers and clinicians to efficiently access and reuse critical information, thereby expediting the diagnosis process for various diseases.

Watershed provides a platform for biological data analysis that integrates secure data management, customizable workflows, and supercomputing resources to enable rapid, large-scale analyses across various omics disciplines. By offering a dedicated bioinformatics team and ready-to-use AI tools, Watershed enhances productivity and collaboration for researchers facing the challenges of complex data interpretation.

Rayca Precision utilizes AI-driven bioinformatics platforms, OncoCrest™ and RSA2™, to analyze genomic and transcriptomic data for personalized cancer treatment strategies. The technology addresses the challenge of cancer heterogeneity by providing precise predictions of drug responses and patient outcomes, enabling tailored therapeutic interventions.

Turing Biosystems develops a software platform that utilizes interpretable AI and automated reasoning to integrate and analyze multimodal clinical and biological data, addressing high failure rates and adverse immune responses in immunotherapy and cell gene therapy. By optimizing clinical outcomes, the platform enables clinicians and biopharma to deliver more effective and safer treatments tailored to individual patient responses.

Helical provides an open-source platform that integrates DNA and mRNA Bio Foundation Models, enabling researchers and developers to leverage biological data for drug discovery applications. The platform facilitates target identification, biomarker discovery, and patient stratification, enhancing the efficiency and effectiveness of therapeutic development.

The startup develops a medical analysis platform that integrates artificial intelligence with computational pathology to enhance diagnostic accuracy in cancer detection. By facilitating real-time collaboration between pathologists and AI, the platform improves decision-making in clinical diagnostics and drug development, ultimately increasing survival rates for cancer patients.

WhiteLab Genomics utilizes a proprietary platform that combines graph knowledge technology and machine learning to optimize the design of payloads and vectors for gene and cell therapies. This technology accelerates the development process, reducing costs and time to market for genomic medicines, making them more accessible to patients.

SilicoGene offers a no-code platform for health-tech teams to manage the entire AI lifecycle in drug discovery, enabling users to prepare bioinformatics data, train models, and deploy them efficiently. The platform provides on-demand access to cost-effective GPUs and ensures data security through HIPAA-compliant infrastructure, facilitating rapid deployment of AI solutions in real-world applications.

AIVIVO LTD develops artificial intelligence systems that generate multi-modal omics data to create OrganoMaps, which connect disease biology with treatment interventions at the organ level. This approach enables the development of targeted medicines for patients by providing insights into organ-specific disease mechanisms.

Genomate Health develops a computational platform that utilizes artificial intelligence to analyze the unique molecular profiles of cancer patients' tumors, enabling oncologists to identify the most effective targeted therapies. This approach improves treatment outcomes by providing data-backed recommendations that consider multiple genetic alterations, significantly increasing the likelihood of positive patient responses.

One Biosciences utilizes single-cell technologies and AI-driven analysis to create high-resolution omics profiles of tumors, enabling precise patient selection and treatment strategies. This approach addresses the complexity of advanced cancer biology, facilitating the development of targeted therapeutics for difficult-to-treat diseases.

The startup develops quantum algorithmic software that utilizes complex network theory and quantum computing to analyze computationally intensive problems in life sciences and data science. This technology accelerates the process of identifying disease origins and potential drug treatments, enabling researchers to leverage quantum computing's capabilities effectively.

Exazyme is an AI-driven protein design tool that utilizes advanced algorithms to predict protein evolutions, enabling biotech companies to achieve superior outcomes with up to 100 times fewer experiments than traditional screening methods. The platform addresses the inefficiencies in protein optimization by allowing users to evaluate multiple protein properties simultaneously while ensuring data security through on-site deployment or API connections.

The startup utilizes a biosynthetic mapping approach combined with experimental data analysis to identify microbial genes that can produce novel drug compounds. This enables pharmaceutical companies and research institutions to access unique molecules with potential new mechanisms for drug development.

Tailwind Biotech provides artificial DNA design services using proprietary artificial intelligence to optimize DNA sequences for bioproduction companies. This technology enhances gene expression and reduces development costs, enabling more efficient and effective genetic engineering processes.

Qubit Pharmaceuticals utilizes quantum physics and advanced computational methods to develop precise drug candidates for complex diseases, focusing on oncology and inflammation. Their proprietary platform, Atlas, enables high-resolution drug design and molecular dynamics simulations, addressing the challenge of creating treatments for previously undruggable targets.

Adaptyv Biosystems is developing a protein engineering platform that utilizes cell-free synthetic biology and nanofluidics to synthesize and test custom-designed proteins. This technology enables the rapid creation of novel proteins for applications in medicine, manufacturing, and energy generation, addressing the limitations of traditional protein design methods.

CoSyne Therapeutics utilizes polymathic AI and genetic computational systems analysis to expedite the development of pharmaceuticals targeting high-risk brain cancer. By digitizing cellular responses, the company enables medical researchers to create a new class of drugs more efficiently and at a lower cost than traditional methods.

The startup develops analytics software that integrates multi-omic data with AI analytics to enhance drug candidate identification and biomarker discovery. This technology enables precision medicine organizations to streamline research processes and significantly reduce time-to-market for new treatments.

BioStrand utilizes its patented LENSai™ Integrated Intelligence Technology to analyze multi-omics data and accelerate antibody drug discovery through advanced computational methods. This technology addresses the inefficiencies in identifying and prioritizing lead drug candidates by providing rapid insights into drug interactions and predicted efficacy.

The startup develops a computational chemistry platform that utilizes data-driven algorithms and quantum chemistry to predict thermodynamic properties of biochemicals, such as solubility and phase equilibria. This technology provides scientists with a robust computing infrastructure for molecular dynamics simulations, facilitating the acceleration of experimental research.

The startup operates a synthetic biology platform that designs and manufactures biomedicines by creating product-specific libraries of synthetic genetic parts. By utilizing bioinformatic analysis of genome-scale data, the company enables clients to engineer novel biomolecules tailored to specific therapeutic properties.

Provides an AI-powered platform for analyzing complex medical data, including transcriptomics, epigenomics, and proteomics, using modular machine learning techniques. This system accelerates research by delivering fast, high-quality insights for identifying therapeutic targets, biomarkers, and disease mechanisms, reducing time and cost compared to traditional methods.

BioStrand accelerates biotherapeutic discovery with its LENS ai™ platform, a SaaS solution that integrates multi-omics, textual, and structural data. Leveraging proprietary HYFTs® technology and advanced AI, including protein language models and vector search, the platform provides actionable insights to streamline target identification and optimize the drug discovery process.

IONLACE develops the _Radiant_ platform, which combines real-world AI with synthetic biology to enable high-resolution proteomic analysis at scale. This technology addresses the limitation of current methods that can only detect a small fraction of circulating proteins, providing researchers with actionable biomarkers for preventative healthcare.

ScienTek accelerates aptamer discovery for challenging protein targets using an AI-powered platform. Their technology combines in silico screening with in vitro validation to identify and optimize nucleic acid sequences with high binding affinity for next-generation therapeutics.

DeltaWave offers an AI-driven deep learning platform designed to enhance medical research by analyzing complex datasets for faster insights. The platform addresses the challenge of slow scientific discovery by enabling researchers to efficiently process and interpret large volumes of medical data.

The startup develops AI-powered precision medicine technology that utilizes multi-omics analysis to decode cellular health and identify molecular causes of diseases. This approach enhances early disease detection and enables targeted therapies for non-invasive prenatal and oncology testing.

Asteria provides a professional platform that features the world's largest curated library of over 500,000 biological strategies, enabling users to leverage 3.8 billion years of evolutionary insights for practical applications. Utilizing AI-driven methodologies, Asteria transforms these nature-inspired strategies into actionable innovations, facilitating the development of solutions across various scientific fields.

SyntheticGestalt develops machine learning models specifically designed for drug discovery, enabling researchers to identify potential drug candidates more efficiently. Their software automates various research processes, reducing time and costs associated with traditional drug development methods.

ENPICOM provides a unified bioinformatics platform that integrates scalable data management, machine learning frameworks, and user-friendly analysis tools for lab and data scientists. This solution streamlines biologics discovery and engineering processes, enabling rapid data retrieval and model deployment while reducing reliance on specialized data science support.

This startup provides an AI-powered platform that automates portfolio analysis and optimization for pharmaceutical and life science companies. It uses machine learning to conduct predictive analysis by integrating competitor, regulatory, demand, and supply data, enabling pharma managers to make data-driven business decisions and identify future opportunities.

This startup develops AI solutions for life sciences, specializing in drug discovery. Their technology designs, conducts, and troubleshoots tasks to accelerate new medication development.

March Therapeutics utilizes proprietary molecular recording technologies and advanced computing to map protein sequences to their functions, enabling high-throughput exploration of enzymatic landscapes. This approach addresses the challenge of efficiently harnessing nature's biomolecular machines for the development of targeted genetic therapies.

BigOmics offers the Omics Playground, an interactive platform that enables biologists to conduct RNA-Seq and proteomics data analysis using over 18 analysis modules and 150 interactive visualizations. This solution addresses the inefficiencies in bioinformatics workflows by allowing researchers to perform complex analyses independently, significantly reducing time spent on data handover and increasing collaboration effectiveness.

The startup develops bioinformatics tools that utilize artificial intelligence for the identification of drug targets and the evolutionary analysis of protein sequences. By enabling the modeling and computational screening of mutant libraries, the company provides pharmaceutical firms with the capability to discover novel drug candidates in previously unexplored areas.

Myria Biosciences develops GEMMS (Genetically Engineered Modular Molecule Scaffolds), a novel class of therapeutic molecules that integrates the properties of small molecules and biologics to create effective drug candidates. Utilizing computational data mining, synthetic biology, and high-throughput experimentation, Myria generates and tests millions of molecules to address unmet medical needs in diseases where existing treatments have failed.

ScienceMachine develops AI systems that automate the analysis of complex biological data, enabling scientists to quickly derive insights from lab-collected datasets like RNA-seq. This technology accelerates drug development for biotech and pharmaceutical companies by streamlining data processing and ensuring no valuable scientific information is overlooked.

The startup utilizes an AI algorithm to design and optimize biocatalysts for the chemical synthesis industry, enhancing resource efficiency and reducing waste. This technology addresses the high costs and environmental impact associated with traditional chemical processes.

The startup operates a biomarker discovery platform that utilizes artificial intelligence and genomic analysis techniques to identify personalized cancer therapies for patients. This approach enhances patient stratification, enabling healthcare providers to deliver more effective treatment options tailored to individual needs.

baSeq is an AI-powered platform that simplifies single-cell RNA sequencing (scRNA-seq) data analysis using natural language processing. It enables researchers to query complex datasets, generate visualizations, and automate the creation of publication-ready figures and text, accelerating biological discovery.

Watershed Informatics provides a bioinformatics platform that automates data analysis across various biological domains, including genomics and proteomics, using customizable workflows and templates. The platform reduces analysis time by 86% and processes 300TB of biological data monthly, enabling researchers to generate insights without extensive coding experience.

The startup offers a food selection platform that utilizes artificial intelligence to generate personalized food and ingredient recommendations based on users' biological and genomic profiles. By analyzing the macro, micro, and phytonutrient content of millions of foods, the platform provides tailored dietary options that align with individual health, nutrition, and taste requirements.

Biomod AI provides an AI-powered platform for biotech researchers to generate DNA sequences and design custom oligos using natural language prompts. This automates complex molecular design tasks, accelerating experimental iteration and discovery in genomics and synthetic biology.

The startup operates a biomedical data analysis platform that provides end-to-end bioinformatics solutions, including access to datasets, analytic workflows, and cloud-computing infrastructure. This platform enables researchers and companies to efficiently transform raw experimental data into actionable insights for new treatments and diagnostics, thereby accelerating the pace of scientific discovery.